The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
After all the positive results and continual good news I can’t see there being any issues on finance !! Some of the recent news has been game changing. I know it’s still up in the air but have you read this article ?
https://seekingalpha.com/samw/article/4294632-summit-therapeutics-upcoming-r-and-d-day-tradeable-event?dr=1#alt1
Nice move again price building and strength gaining each session. Hope it reflects well Monday
Where is the money coming from to finance remainder of phase 3-what dilutive effect will it have?
We have had a lot of good news recently reckon this will be a long awaited major success story
RNS is about as good as it gets at this early stage. NASDAQ seem to like the news.
Great news rns.
Looking good again now going forward.
Cracking rns ....good news after good news after good news
Fingers crossed for Phase III
The following sentiment could be one of the reasons in the sudden SP increase for which I note further interest on the NASDAQ this evening;
Summit Therapeutics' Upcoming R&D Day Could Be A Tradeable Event:
http://seekingalpha.com/article/4294632-summit-therapeutics-upcoming-r-and-d-day-tradeable-event?dr=1#alt1
Interesting day ahead . Good luck.
£100,000 Buy !! Something cooking ??
GLA
Thanks pharma confirms with Chris last night 29p equivalent
Take the dollar price - divide by 5 and apply the exchange rate - so would be $1.79/5/1.23 = 29p
US = 5 ordinary shares on AIM - current exchange $1.23 to the pound
I think one US depository share = 7 ordinary shares in Summit. But don't quote me.
https://www.investopedia.com/ask/answers/06/adshares.asp
It doesn’t - Chris normally gives a good explanation of the conversion formula
am i being thick but how can $1-77 = 20p
There is 148,000 shares waiting to buy on the Nasdaq at 1.77 which is about 29p... why do you think the huge disconnect ?
So 1.80 close = nearly 30p? Going to be a great day tomorrow then as uk line follows Nasdaq
stew200 - Summ is currently 14.38 % up at $1.75 = £0.29p which is the highest rise this year.I also note that we have not had the interim results out yet for the 6 months ended 31st July 2019 which are normally out by now - is there something brewing ?
It’s certainly moving over the pond take a look
How can this share price move until long term finance sorted out? They run out of cash in a few months time. What is to prevent the 49% holder buy this for a few % points over the prevailing share price? Clearly, no big pharma was interested. Been here for years-not much faith in CEO-interested to see CFO left-despite been given a shed load of share options at around current share price levels.
GLA.
Good day over the pond
Summit Therapeutics to Host R&D Day 7 October 2019
https://www.summitplc.com/app/uploads/2019/09/2019_RNS_33-RD-Day-alert-FINAL.pdf
There is more evidence out now